Published in Drug Week, April 23rd, 2004
Revenues for the year ended December 31, 2003, were $9,014,781, a 25% increase over the year ended December 31, 2002. This increase was primarily driven by growth in demand for high-throughput screening support services, mouse genetics services, and protein expression services.
Revenues for the quarter ended December 31, 2003, were $2,248,246, a 24% increase over the same period in 2002. The company's revenues are entirely attributed to the company's wholly owned operating subsidiary, Cell & Molecular Technologies, Inc.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week